

Richard Holt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1874284/publications.pdf>

Version: 2024-02-01

246
papers

9,231
citations

43973

48
h-index

49773

87
g-index

264
all docs

264
docs citations

264
times ranked

9254
citing authors

#	ARTICLE	IF	CITATIONS
1	Introduction to the development of complex interventions. <i>Postgraduate Medical Journal</i> , 2022, 98, 895-899.	0.9	1
2	Healthcare resource use and costs for people with type 2 diabetes mellitus with and without severe mental illness in England: longitudinal matched-cohort study using the Clinical Practice Research Datalink. <i>British Journal of Psychiatry</i> , 2022, 221, 402-409.	1.7	10
3	Liraglutide and the management of overweight and obesity in people with severe mental illness: qualitative sub-study. <i>BMC Psychiatry</i> , 2022, 22, 21.	1.1	5
4	User-driven open-source artificial pancreas systems and patient-reported outcomes: A missed opportunity?. <i>Diabetic Medicine</i> , 2022, 39, e14797.	1.2	4
5	The lived experience of severe mental illness and long-term conditions: a qualitative exploration of service user, carer, and healthcare professional perspectives on self-managing co-existing mental and physical conditions. <i>BMC Psychiatry</i> , 2022, 22, .	1.1	14
6	Comparison of normal distribution-based and nonparametric decision limits on the GHG2000 score for detecting growth hormone misuse (doping) in sport. <i>Biometrical Journal</i> , 2021, 63, 187-200.	0.6	4
7	Treatment for comorbid depressive disorder or subthreshold depression in diabetes mellitus: Systematic review and meta-analysis. <i>Brain and Behavior</i> , 2021, 11, e01981.	1.0	57
8	The effects of recombinant human insulin-like growth factor-1/insulin-like growth factor binding protein-3 administration on lipid and carbohydrate metabolism in recreational athletes. <i>Clinical Endocrinology</i> , 2021, 94, 551-562.	1.2	2
9	Diabetes management during cardiac surgery in the UK: A survey. <i>Diabetic Medicine</i> , 2021, 38, e14388.	1.2	2
10	Impact of severe mental illness on healthcare use and health outcomes for people with type 2 diabetes: a longitudinal observational study in England. <i>British Journal of General Practice</i> , 2021, 71, e565-e573.	0.7	18
11	Consequences of the COVID-19 pandemic for patients with metabolic diseases. <i>Nature Metabolism</i> , 2021, 3, 289-292.	5.1	33
12	The use of liraglutide 3.0Åmg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double-blind, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1262-1271.	2.2	28
13	Impact of diabetes on COVID-19 and other infection: Report from the 22nd Hong Kong Diabetes and Cardiovascular Risk Factors East Meets West Symposium. <i>Diabetic Medicine</i> , 2021, 38, e14547.	1.2	9
14	Living with diabetes alongside a severe mental illness: A qualitative exploration with people with severe mental illness, family members and healthcare staff. <i>Diabetic Medicine</i> , 2021, 38, e14562.	1.2	25
15	Exploring determinants of self-management in adults with severe mental illness: a qualitative evidence synthesis. <i>BJPsych Open</i> , 2021, 7, S13-S13.	0.3	2
16	The Optimising Cardiac Surgery ouTcomes in People with diabetes (OCTOPuS) randomised controlled trial to evaluate an outpatient pre-cardiac surgery diabetes management intervention: a study protocol. <i>BMJ Open</i> , 2021, 11, e050919.	0.8	5
17	Developing an intervention to optimise the outcome of cardiac surgery in people with diabetes: the OCTOPuS pilot study. <i>Pilot and Feasibility Studies</i> , 2021, 7, 157.	0.5	1
18	Determinants of Physical Health Self-Management Behaviours in Adults With Serious Mental Illness: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2021, 12, 723962.	1.3	11

#	ARTICLE	IF	CITATIONS
19	The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , 2021, 44, 2589-2625.	4.3	244
20	The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2021, 64, 2609-2652.	2.9	128
21	Completion of annual diabetes care processes and mortality: A cohort study using the <scp>National Diabetes Audit for England and Wales</scp>. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2728-2740.	2.2	16
22	Exploring the facilitators, barriers, and strategies for self-management in adults living with severe mental illness, with and without long-term conditions: A qualitative evidence synthesis. <i>PLoS ONE</i> , 2021, 16, e0258937.	1.1	15
23	COVID-19 and metabolic disease: mechanisms and clinical management. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 786-798.	5.5	155
24	Prevalence of Overweight and Obesity in People With Severe Mental Illness: Systematic Review and Meta-Analysis. <i>Frontiers in Endocrinology</i> , 2021, 12, 769309.	1.5	42
25	Editorial: Keeping the Body in Mind: Scientific Effort in Advocating the Best Outcomes for People Living With Severe Mental Illness. <i>Frontiers in Endocrinology</i> , 2021, 12, 831933.	1.5	1
26	Diabetes in the UK: 2019. <i>Diabetic Medicine</i> , 2020, 37, 242-247.	1.2	111
27	How 25 years of psychosocial research has contributed to a better understanding of the links between depression and diabetes. <i>Diabetic Medicine</i> , 2020, 37, 383-392.	1.2	39
28	The role of community pharmacists in the delivery of diabetes care. <i>Diabetic Medicine</i> , 2020, 37, 1653-1654.	1.2	2
29	Diabetic Medicine: my swan song. <i>Diabetic Medicine</i> , 2020, 37, 1965-1965.	1.2	0
30	Dried blood spots and HbA_{1c}. <i>Diabetic Medicine</i> , 2020, 37, 1417-1417.	1.2	0
31	The role of community pharmacists and their position in the delivery of diabetes care: an update for medical professionals. <i>Postgraduate Medical Journal</i> , 2020, 96, 473-479.	0.9	17
32	The James Lind Alliance Research Priorities for Diabetes revisited. <i>Diabetic Medicine</i> , 2020, 37, 511-512.	1.2	0
33	Some young adults with cystic fibrosisâ€related diabetes may safely stop insulin without any adverse clinical sequelae. <i>Diabetic Medicine</i> , 2020, 37, 1205-1208.	1.2	1
34	COVIDâ€19 and diabetes. <i>Diabetic Medicine</i> , 2020, 37, 723-725.	1.2	125
35	How psychosocial and behavioural research has shaped our understanding of diabetes. <i>Diabetic Medicine</i> , 2020, 37, 377-379.	1.2	6
36	The importance of facts and figures in diabetes care. <i>Diabetic Medicine</i> , 2020, 37, 173-173.	1.2	0

#	ARTICLE	IF	CITATIONS
37	Non-attendance at diabetes outpatient appointments: a systematic review. <i>Diabetic Medicine</i> , 2020, 37, 1427-1442.	1.2	61
38	Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes. <i>Drugs</i> , 2020, 80, 147-165.	4.9	13
39	Diabetes, Depression, and Cognitive Disorders. <i>Endocrinology</i> , 2020, , 687-714.	0.1	0
40	Diabetes distress. <i>Diabetic Medicine</i> , 2019, 36, 793-794.	1.2	0
41	The Use and Abuse of Growth Hormone in Sports. <i>Endocrine Reviews</i> , 2019, 40, 1163-1185.	8.9	34
42	Using health economics to count the cost of diabetes. <i>Diabetic Medicine</i> , 2019, 36, 925-926.	1.2	2
43	The Management of Obesity in People with Severe Mental Illness: An Unresolved Conundrum. <i>Psychotherapy and Psychosomatics</i> , 2019, 88, 327-332.	4.0	20
44	Innovation in diabetes: insulin, research priorities and new recruitment. <i>Diabetic Medicine</i> , 2019, 36, 1523-1525.	1.2	0
45	Cystic fibrosis-related diabetes: the missing evidence. <i>Diabetic Medicine</i> , 2019, 36, 1327-1328.	1.2	0
46	Learning about diabetes through epidemiology. <i>Diabetic Medicine</i> , 2019, 36, 1195-1198.	1.2	1
47	Association Between Antipsychotic Medication Use and Diabetes. <i>Current Diabetes Reports</i> , 2019, 19, 96.	1.7	88
48	Assessing the outcomes of pregnancies of women with diabetes. <i>Diabetic Medicine</i> , 2019, 36, 139-141.	1.2	0
49	Transforming mental well-being for people with diabetes: research recommendations from Diabetes UK's 2019 Diabetes and Mental Well-Being Workshop. <i>Diabetic Medicine</i> , 2019, 36, 1532-1538.	1.2	36
50	Global access to insulin. <i>Diabetic Medicine</i> , 2019, 36, 663-664.	1.2	0
51	Predicting the future: Diabetes and Brexit. <i>Diabetic Medicine</i> , 2019, 36, 397-398.	1.2	2
52	The James Lind Alliance research priorities for diabetes. <i>Diabetic Medicine</i> , 2019, 36, 267-268.	1.2	0
53	Structured lifestyle education for people With Schizophrenia (STEPWISE): mixed methods process evaluation of a group-based lifestyle education programme to support weight loss in people with schizophrenia. <i>BMC Psychiatry</i> , 2019, 19, 358.	1.1	13
54	Liraglutide and the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis: protocol for a pilot trial. <i>Trials</i> , 2019, 20, 633.	0.7	15

#	ARTICLE	IF	CITATIONS
55	Provision of weight loss programmes and their influence on weight after 1 year: follow-up survey of usual care in the STEPWISE study. <i>BJPsych Bulletin</i> , 2019, 43, 245-246.	0.7	1
56	Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial. <i>British Journal of Psychiatry</i> , 2019, 214, 63-73.	1.7	77
57	Exploring Severe Mental Illness and Diabetes: Protocol for a Longitudinal, Observational, and Qualitative Mixed Methods Study. <i>JMIR Research Protocols</i> , 2019, 8, e13407.	0.5	6
58	Primary care management of cardiovascular risk for people with severe mental illnesses: the Primrose research programme including cluster RCT. <i>Programme Grants for Applied Research</i> , 2019, 7, 1-98.	0.4	6
59	Diabetes, Depression, and Cognitive Disorders. <i>Endocrinology</i> , 2019, , 1-28.	0.1	0
60	Diabetic Medicine and Diabetes <sc>UK</sc>. <i>Diabetic Medicine</i> , 2018, 35, 291-291.	1.2	0
61	Unique challenges of cystic fibrosis-related diabetes. <i>Diabetic Medicine</i> , 2018, 35, 1181-1188.	1.2	29
62	Update of Diabetes <sc>UK</sc> Evidence-Based Nutritional Guidelines for 2018: a celebration of two leading journals working together to improve nutritional science and dietetic care for people living with diabetes. <i>Diabetic Medicine</i> , 2018, 35, 539-540.	1.2	1
63	Clinical and cost-effectiveness of an intervention for reducing cholesterol and cardiovascular risk for people with severe mental illness in English primary care: a cluster randomised controlled trial. <i>Lancet Psychiatry</i> , 2018, 5, 145-154.	3.7	66
64	Clinical aspects of diabetes in pregnancy. <i>Diabetic Medicine</i> , 2018, 35, 159-159.	1.2	2
65	Hyperandrogenism controversy in elite women's sport: an examination and critique of recent evidence. <i>British Journal of Sports Medicine</i> , 2018, 52, 1481-1482.	3.1	31
66	Incidence of filled antidepressant prescriptions among people with newly diagnosed diabetes and its interaction with occupational status within the working population of Denmark 1996-2010. <i>Primary Care Diabetes</i> , 2018, 12, 305-311.	0.9	4
67	Technology: an increasingly important component in the management of diabetes. <i>Diabetic Medicine</i> , 2018, 35, 407-408.	1.2	2
68	Mechanisms in endocrinology: Antipsychotic medication and type 2 diabetes and impaired glucose regulation. <i>European Journal of Endocrinology</i> , 2018, 178, R245-R258.	1.9	33
69	Diabetes, Depression, and Cognitive Disorders. <i>Endocrinology</i> , 2018, , 1-27.	0.1	1
70	Reducing the burden of diabetes complications. <i>Diabetic Medicine</i> , 2018, 35, 7-7.	1.2	2
71	Emerging adulthood and Type 1 diabetes: insights from the DAWN2 Study. <i>Diabetic Medicine</i> , 2018, 35, 203-213.	1.2	36
72	Language Matters-the campaign continues!. <i>Diabetic Medicine</i> , 2018, 35, 1627-1627.	1.2	1

#	ARTICLE	IF	CITATIONS
73	A correction to the age-adjustment of the GH-2000 score used in the detection of growth hormone misuse. BMC Research Notes, 2018, 11, 650.	0.6	4
74	Hypoglycaemia: under-reported and under-treated. Diabetic Medicine, 2018, 35, 1143-1143.	1.2	0
75	Pumps or Multiple Daily Injections in Pregnancy Involving Type 1 Diabetes: A Prespecified Analysis of the CONCEPTT Randomized Trial. Diabetes Care, 2018, 41, 2471-2479.	4.3	87
76	Editor's Selection: This Month's Highlighted Articles. Diabetic Medicine, 2018, 35, 1469-1469.	1.2	0
77	Psychosocial impact of diabetes. Diabetic Medicine, 2018, 35, 675-676.	1.2	1
78	Joint British Diabetes Societies for Inpatient Care: clinical guidelines and improving inpatient diabetes care. Diabetic Medicine, 2018, 35, 988-991.	1.2	16
79	Clinical guidelines in diabetes. Diabetic Medicine, 2018, 35, 987-987.	1.2	0
80	Language matters: a UK perspective. Diabetic Medicine, 2018, 35, 1635-1641.	1.2	21
81	Involving the right people in diabetes research. Diabetic Medicine, 2018, 35, 831-831.	1.2	0
82	Language matters. Addressing the use of language in the care of people with diabetes: position statement of the English Advisory Group. Diabetic Medicine, 2018, 35, 1630-1634.	1.2	36
83	Diabetes, Depression, and Cognitive Disorders. Endocrinology, 2018, , 689-716.	0.1	0
84	Novel markers to detect recombinant human insulin-like growth factor-1 (rhIGF-1)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes. Drug Testing and Analysis, 2017, 9, 30-37.	1.6	4
85	The Clonal Invariant NKT Cell Repertoire in People with Type 1 Diabetes Is Characterized by a Loss of Clones Expressing High-Affinity TCRs. Journal of Immunology, 2017, 198, 1452-1459.	0.4	9
86	Development of an acceptable and feasible self-management group for children, young people and families living with Type 1 diabetes. Diabetic Medicine, 2017, 34, 813-820.	1.2	12
87	Understanding of the causes and management of diabetic foot disease. Diabetic Medicine, 2017, 34, 303-304.	1.2	1
88	The burden of diabetes self-management in children and young adults. Diabetic Medicine, 2017, 34, 747-747.	1.2	3
89	Adherence to NICE guidance on lifestyle advice for people with schizophrenia: A survey. BJPsych Bulletin, 2017, 41, 137-144.	0.7	9
90	Deficiencies in postgraduate training for healthcare professionals who provide diabetes education and support: results from the Diabetes Attitudes, Wishes and Needs (<sc>DAWN</sc>) study. Diabetic Medicine, 2017, 34, 1074-1083.	1.2	38

#	ARTICLE	IF	CITATIONS
91	Diabetes and risk. <i>Diabetic Medicine</i> , 2017, 34, 459-459.	1.2	1
92	Gestational diabetes: the controversy continues. <i>Diabetic Medicine</i> , 2017, 34, 7-7.	1.2	0
93	A crisis in diabetes research funding. <i>Diabetic Medicine</i> , 2017, 34, 1331-1331.	1.2	2
94	The language of diabetes: the good, the bad and the ugly. <i>Diabetic Medicine</i> , 2017, 34, 1495-1497.	1.2	11
95	Relative changes in earned income five years after diagnosis with diabetes: A register based study 1996-2012. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1506-1514.	1.2	3
96	Effectiveness and cost-effectiveness of a cardiovascular risk prediction algorithm for people with severe mental illness (PRIMROSE). <i>BMJ Open</i> , 2017, 7, e018181.	0.8	13
97	A core outcome set for evaluating self-management interventions in people with comorbid diabetes and severe mental illness: study protocol for a modified Delphi study and systematic review. <i>Trials</i> , 2017, 18, 70.	0.7	9
98	Gestational diabetes: paradigm lost?. <i>Diabetic Medicine</i> , 2017, 34, 8-13.	1.2	11
99	Diabetes and depression in Denmark 1996-2010: national data stratified by occupational status and annual income. <i>Diabetic Medicine</i> , 2017, 34, 108-114.	1.2	14
100	Household composition and psychological health: Results of the Second Diabetes Attitudes, Wishes and Needs (DAWN2) study. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 340-346.	1.2	7
101	Illusory nature of achieving glycaemic control. <i>Diabetic Medicine</i> , 2017, 34, 1655-1655.	1.2	0
102	The Effectiveness of Pharmacological and Non-Pharmacological Interventions for Improving Glycaemic Control in Adults with Severe Mental Illness: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2017, 12, e0168549.	1.1	35
103	Nutritional advice in diabetes: a recipe for confusion. <i>Diabetic Medicine</i> , 2016, 33, 563-564.	1.2	1
104	Putting feet first: rising to the challenge. <i>Diabetic Medicine</i> , 2016, 33, 1463-1463.	1.2	1
105	Reflections on a year at <i>Diabetic Medicine</i> . <i>Diabetic Medicine</i> , 2016, 33, 1611-1611.	1.2	0
106	Reflections on changing paradigms. <i>Diabetic Medicine</i> , 2016, 33, 1011-1012.	1.2	1
107	Correlates and outcomes of worries about hypoglycemia in family members of adults with diabetes: The second Diabetes Attitudes, Wishes and Needs (DAWN2) study. <i>Journal of Psychosomatic Research</i> , 2016, 89, 69-77.	1.2	14
108	Brexit and diabetes. <i>Diabetic Medicine</i> , 2016, 33, 1171-1171.	1.2	1

#	ARTICLE	IF	CITATIONS
109	The old and the new. <i>Diabetic Medicine</i> , 2016, 33, 9-9.	1.2	0
110	Education and training: the key to success in diabetes care. <i>Diabetic Medicine</i> , 2016, 33, 147-147.	1.2	1
111	Editor's Selection: This Month's Highlighted Articles. <i>Diabetic Medicine</i> , 2016, 33, 279-279.	1.2	1
112	Hypoglycaemia: costs, insulins and prevention. <i>Diabetic Medicine</i> , 2016, 33, 419-420.	1.2	0
113	Personalized medicine for diabetes: a special issue. <i>Diabetic Medicine</i> , 2016, 33, 711-711.	1.2	3
114	Diabetes and childhood. <i>Diabetic Medicine</i> , 2016, 33, 1311-1311.	1.2	0
115	Correlates of psychological outcomes in people with diabetes: results from the second Diabetes Attitudes, Wishes and Needs (<sc>DAWN</sc> ²) study. <i>Diabetic Medicine</i> , 2016, 33, 1194-1203.	1.2	51
116	Diabetic retinopathy: a success story for screening. <i>Diabetic Medicine</i> , 2016, 33, 863-863.	1.2	3
117	Statistical methodology for age-adjustment of the GH-2000 score detecting growth hormone misuse. <i>BMC Medical Research Methodology</i> , 2016, 16, 147.	1.4	6
118	STEPWISE "Structured lifestyle Education for People With SchizophrEnia: a study protocol for a randomised controlled trial. <i>Trials</i> , 2016, 17, 475.	0.7	12
119	Evaluating the clinical and cost effectiveness of a behaviour change intervention for lowering cardiovascular disease risk for people with severe mental illnesses in primary care (PRIMROSE study): study protocol for a cluster randomised controlled trial. <i>Trials</i> , 2016, 17, 80.	0.7	17
120	Growth Hormone and Insulin-Like Growth Factor-1. <i>Frontiers of Hormone Research</i> , 2016, 47, 101-114.	1.0	35
121	Correlates of psychological care strategies for people with diabetes in the second Diabetes Attitudes, Wishes and Needs (<sc>DAWN</sc> ²) study. <i>Diabetic Medicine</i> , 2016, 33, 1174-1183.	1.2	18
122	Correlates of psychological outcomes among family members of people with diabetes in the second Diabetes Attitudes, Wishes and Needs (<sc>DAWN</sc> ²) study. <i>Diabetic Medicine</i> , 2016, 33, 1184-1193.	1.2	19
123	The use of glucose measurements to improve screening for diabetes in clinical practice. <i>British Journal of Diabetes</i> , 2016, 16, 123.	0.1	0
124	A decade in diabetes specialist services, 2000 to 2011, in England: the views of consultant diabetologists and diabetes specialist nurses amidst persistent healthcare delivery change. <i>Diabetic Medicine</i> , 2015, 32, 1662-1666.	1.2	3
125	The prevention of diabetes and cardiovascular disease in people with schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2015, 132, 86-96.	2.2	25
126	Depression and diabetes: treatment and health-care delivery. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 472-485.	5.5	156

#	ARTICLE	IF	CITATIONS
127	Cardiovascular Risk Prediction Models for People With Severe Mental Illness. <i>JAMA Psychiatry</i> , 2015, 72, 143.	6.0	127
128	Could the Discrepancy in Perceived Emotional Care Received and Provided Be a Barrier to Active Diabetes Self-management? Insights From the Second Diabetes Attitudes, Wishes and Needs (DAWN2) Study. <i>Diabetes Care</i> , 2015, 39, dc150674.	4.3	2
129	Medical and Ethical Concerns Regarding Women With Hyperandrogenism and Elite Sport. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 825-827.	1.8	26
130	The development of decision limits for the GH-2000 detection methodology using additional insulin-like growth factor-1 and amino-terminal pro-peptide of type III collagen assays. <i>Drug Testing and Analysis</i> , 2015, 7, 745-755.	1.6	26
131	Poor monitoring of physical health in patients referred to a mood disorders service. <i>Therapeutic Advances in Psychopharmacology</i> , 2015, 5, 22-25.	1.2	8
132	Glyburide for Gestational Diabetes. <i>JAMA Pediatrics</i> , 2015, 169, 427.	3.3	8
133	The Effects of Recombinant Human Insulin-Like Growth Factor-I/Insulin-Like Growth Factor Binding Protein-3 Administration on Body Composition and Physical Fitness in Recreational Athletes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3126-3131.	1.8	11
134	The Role of Mobile Applications in Improving Alcohol Health Literacy in Young Adults With Type 1 Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2015, 9, 1313-1320.	1.3	25
135	Diabetes mellitus and severe mental illness: mechanisms and clinical implications. <i>Nature Reviews Endocrinology</i> , 2015, 11, 79-89.	4.3	119
136	A new measure of multimorbid illness and treatment representations: The example of diabetes and depression. <i>Journal of Affective Disorders</i> , 2015, 174, 192-200.	2.0	7
137	Kaleidoscope model of diabetes care: time for a rethink?. <i>Diabetic Medicine</i> , 2014, 31, 522-530.	1.2	27
138	NIDDK International Conference Report on Diabetes and Depression: Current Understanding and Future Directions. <i>Diabetes Care</i> , 2014, 37, 2067-2077.	4.3	111
139	Alcohol health literacy in young adults with Type 1 diabetes and its impact on diabetes management. <i>Diabetic Medicine</i> , 2014, 31, 1625-1630.	1.2	33
140	Diabetes and Depression. <i>Current Diabetes Reports</i> , 2014, 14, 491.	1.7	327
141	Review of reviews 2014: a virtual issue. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 481-482.	2.2	0
142	Biochemical Markers of Insulin-Like Growth Factor-I Misuse in Athletes: The Response of Serum IGF-I, Procollagen Type III Amino-Terminal Propeptide, and the GH-2000 Score to the Administration of rhIGF-I/rhIGF Binding Protein-3 Complex. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 2259-2268.	1.8	14
143	The use of oral hypoglycaemic agents in pregnancy. <i>Diabetic Medicine</i> , 2014, 31, 282-291.	1.2	37
144	Diabetes Attitudes, Wishes and Needs second study (DAWN2 ^{2,c}): Cross-national benchmarking indicators for family members living with people with diabetes. <i>Diabetic Medicine</i> , 2013, 30, 778-788.	1.2	216

#	ARTICLE	IF	CITATIONS
145	Diabetes Attitudes, Wishes and Needs second study (DAWN2 ^{â„†}): Cross ^{â€} national comparisons on barriers and resources for optimal care ^{â€} healthcare professional perspective. <i>Diabetic Medicine</i> , 2013, 30, 789-798.	1.2	137
146	The effects of two weeks of recombinant growth hormone administration on the response of IGF-I and N-terminal pro-peptide of collagen type III (P-III-NP) during a single bout of high resistance exercise in resistance trained young men. <i>Growth Hormone and IGF Research</i> , 2013, 23, 76-80.	0.5	6
147	The use of insulin analogues in pregnancy. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 888-900.	2.2	55
148	Insulin-like growth factor-I (IGF-I) misuse in athletes and potential methods for detection. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 9669-9683.	1.9	17
149	Diabetes Attitudes Wishes and Needs 2 (DAWN2): A multinational, multi-stakeholder study of psychosocial issues in diabetes and person-centred diabetes care. <i>Diabetes Research and Clinical Practice</i> , 2013, 99, 174-184.	1.1	195
150	Antidepressant Medication as a Risk Factor for Type 2 Diabetes and Impaired Glucose Regulation. <i>Diabetes Care</i> , 2013, 36, 3337-3345.	4.3	140
151	The relationship between depression, anxiety and cardiovascular disease: Findings from the Hertfordshire Cohort Study. <i>Journal of Affective Disorders</i> , 2013, 150, 84-90.	2.0	42
152	Identifying risk and preventing progression to Type ^{âˆ2} diabetes in vulnerable and disadvantaged adults: a pragmatic review. <i>Diabetic Medicine</i> , 2013, 30, 16-25.	1.2	26
153	Social Networking and Understanding Alcohol-Associated Risk for People with Type 1 Diabetes: Friend or Foe?. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, 308-314.	2.4	31
154	A new DAWN: Improving the psychosocial management of diabetes. <i>Indian Journal of Endocrinology and Metabolism</i> , 2013, 17, 95.	0.2	19
155	Detecting growth hormone misuse in athletes. <i>Indian Journal of Endocrinology and Metabolism</i> , 2013, 17, 18.	0.2	11
156	The association between diabetes and an episode of depressive symptoms in the 2002 World Health Survey: an analysis of 231 ^{âˆ797} individuals from 47 countries. <i>Diabetic Medicine</i> , 2013, 30, e208-14.	1.2	72
157	Diabetes Attitudes, Wishes and Needs second study (DAWN2 ^{â„†}): Cross ^{â€} national benchmarking of diabetes ^{â€} related psychosocial outcomes for people with diabetes. <i>Diabetic Medicine</i> , 2013, 30, 767-777.	1.2	540
158	Biochemical markers of recombinant human insulin ^{â€} like growth factor ^{â€} (rhIGF ^{â€})/rhIGF binding protein ^{â€} (rhIGFBP ^{â€}) misuse in athletes. <i>Drug Testing and Analysis</i> , 2013, 5, 843-849.	1.6	11
159	The publication of Diabetes UK position statements and care recommendations; a virtual issue. <i>Diabetic Medicine</i> , 2012, , no-no.	1.2	0
160	Dialogue on Diabetes and Depression: Dealing with the double burden of co-morbidity. <i>Journal of Affective Disorders</i> , 2012, 142, S1-S3.	2.0	36
161	Key concepts in screening for depression in people with diabetes. <i>Journal of Affective Disorders</i> , 2012, 142, S72-S79.	2.0	19
162	The development of decision limits for the implementation of the GH-2000 detection methodology using current commercial insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays. <i>Growth Hormone and IGF Research</i> , 2012, 22, 53-58.	0.5	32

#	ARTICLE	IF	CITATIONS
163	Psychosocial support for people with diabetes: past, present and future. <i>Diabetic Medicine</i> , 2012, 29, 1358-1360.	1.2	39
164	Weight in Infancy and Adult Calcium Absorption as Determinants of Bone Mineral Density in Adult Men: The Hertfordshire Cohort Study. <i>Calcified Tissue International</i> , 2012, 91, 416-422.	1.5	4
165	The effects of a freeze-thaw cycle and pre-analytical storage temperature on the stability of insulin-like growth factor and pro-collagen type III N-terminal propeptide concentrations: Implications for the detection of growth hormone misuse in athletes. <i>Drug Testing and Analysis</i> , 2012, 4, 455-459.	1.6	12
166	Screening tools used for measuring depression among people with Type 1 and Type 2 diabetes: a systematic review. <i>Diabetic Medicine</i> , 2012, 29, 164-175.	1.2	127
167	Alcohol-associated risks for young adults with Type 1 diabetes: a narrative review. <i>Diabetic Medicine</i> , 2012, 29, 434-440.	1.2	33
168	Psychological Burden of Diabetes and What It Means to People with Diabetes. , 2012, , 1-22.		6
169	Diabetes and Doping. , 2012, , 167-191.		0
170	Growth hormone doping: a review. <i>Open Access Journal of Sports Medicine</i> , 2011, 2, 99.	0.6	10
171	Weight Gain and Changes in Metabolic Variables following Olanzapine Treatment in Schizophrenia and Bipolar Disorder. <i>Clinical Drug Investigation</i> , 2011, 31, 455-482.	1.1	93
172	The implications of the new International Association of Diabetes and Pregnancy Study Groups (IADPSG) diagnostic criteria for gestational diabetes. <i>Diabetic Medicine</i> , 2011, 28, 382-385.	1.2	32
173	The publication of Diabetes UK position statements and care recommendations. <i>Diabetic Medicine</i> , 2011, 28, 507-507.	1.2	1
174	Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. <i>Clinical Endocrinology</i> , 2011, 74, 141-147.	1.2	64
175	Beyond reasonable doubt: catching the drug cheats at the London Olympic. <i>Significance</i> , 2011, 8, 5-9.	0.3	0
176	Screening for gestational diabetes mellitus: cost utility of different screening strategies based on a woman's individual risk of disease. <i>Diabetologia</i> , 2011, 54, 256-263.	2.9	43
177	Detecting growth hormone abuse in athletes. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 401, 449-462.	1.9	26
178	The use of growth hormone (GH)-dependent markers in the detection of GH abuse in sport: Physiological intra-individual variation of IGF-I, type 3 pro-collagen (P-III-P) and the GH-2000 detection score. <i>Clinical Endocrinology</i> , 2010, 72, 520-526.	1.2	43
179	The use of growth hormone (GH)-dependent markers in the detection of GH abuse in sport: Physiological intra-individual variation of IGF-I, type 3 pro-collagen (P-III-P) and the GH-2000 detection score: Authors' response. <i>Clinical Endocrinology</i> , 2010, 73, 274.	1.2	3
180	Bromocriptine: old drug, new formulation and new indication. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 1048-1057.	2.2	90

#	ARTICLE	IF	CITATIONS
181	Insulin initiation in Type 2 diabetes: the implications of the 4â€ƒ study. Diabetic Medicine, 2010, 27, 1-3.	1.2	8
182	The prevalence of undiagnosed metabolic abnormalities in people with serious mental illness. Journal of Psychopharmacology, 2010, 24, 867-873.	2.0	61
183	The fifth UK paediatric diabetes services survey: meeting guidelines and recommendations?. Archives of Disease in Childhood, 2010, 95, 837-840.	1.0	42
184	The GH-2004 project: the response of IGF1 and type III pro-collagen to the administration of exogenous GH in non-Caucasian amateur athletes. European Journal of Endocrinology, 2010, 163, 45-54.	1.9	25
185	Gestational Diabetes Mellitus: NICE for the U.S.? A Comparison of the American Diabetes Association and the American College of Obstetricians and Gynecologists Guidelines With the U.K. National Institute for Health and Clinical Excellence Guidelines: Response to Simmons et al.. Diabetes Care, 2010, 33, e46-e47.	4.3	3
186	Insulin-like Growth Factor I and Insulin and Their Abuse in Sport. Endocrinology and Metabolism Clinics of North America, 2010, 39, 33-43.	1.2	10
187	Serum Insulin-Like Growth Factor-I and Pro-Collagen Type III N-Terminal Peptide in Adolescent Elite Athletes: Implications for the Detection of Growth Hormone Abuse in Sport. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2969-2976.	1.8	21
188	Intentional Weight Loss in Overweight and Obese Patients With Severe Mental Illness. Journal of Clinical Psychiatry, 2010, 71, 800-805.	1.1	30
189	Influence of ethnicity on IGFâ€ƒ and procollagen III peptide (Pâ€ƒ) in elite athletes and its effect on the ability to detect GH abuse. Clinical Endocrinology, 2009, 70, 161-168.	1.2	42
190	Insulin analogues: a step forward in the care in diabetes. Diabetes, Obesity and Metabolism, 2009, 11, 1-4.	2.2	1
191	Obesity, serious mental illness and antipsychotic drugs. Diabetes, Obesity and Metabolism, 2009, 11, 665-679.	2.2	130
192	Diabetes specialist nurses and role evolvment: a survey by Diabetes UK and ABCD of specialist diabetes services 2007. Diabetic Medicine, 2009, 26, 560-565.	1.2	35
193	The relationship between depression and diabetes mellitus: findings from the Hertfordshire Cohort Study. Diabetic Medicine, 2009, 26, 641-648.	1.2	78
194	A national survey of the current state of screening services for diabetic retinopathy: ABCDâ€ƒ Diabetes UK survey of specialist diabetes services 2006. Diabetic Medicine, 2009, 26, 1301-1305.	1.2	15
195	Is human growth hormone an ergogenic aid?. Drug Testing and Analysis, 2009, 1, 412-418.	1.6	12
196	Detecting growth hormone abuse in athletes. Drug Testing and Analysis, 2009, 1, 426-433.	1.6	21
197	A determination of the pre-analytical storage conditions for insulin like growth factor-I and type III procollagen peptide. Growth Hormone and IGF Research, 2009, 19, 43-50.	0.5	18
198	The history of doping and growth hormone abuse in sport. Growth Hormone and IGF Research, 2009, 19, 320-326.	0.5	78

#	ARTICLE	IF	CITATIONS
199	Moving one step closer to catching the GH cheats: The GH-2004 experience. Growth Hormone and IGF Research, 2009, 19, 346-351.	0.5	12
200	IGF-I abuse in sport: Current knowledge and future prospects for detection. Growth Hormone and IGF Research, 2009, 19, 408-411.	0.5	18
201	Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). European Psychiatry, 2009, 24, 412-424.	0.1	751
202	The Effect of Sulphonylureas on the Microvascular and Macrovascular Complications of Diabetes. Cardiovascular Drugs and Therapy, 2008, 22, 207-213.	1.3	26
203	Growth hormone, IGF and insulin and their abuse in sport. British Journal of Pharmacology, 2008, 154, 542-556.	2.7	148
204	The effectiveness of glibenclamide in women with gestational diabetes. Diabetes, Obesity and Metabolism, 2008, 10, 906-911.	2.2	20
205	Association of British Clinical Diabetologists (ABCD) and Diabetes-UK survey of specialist diabetes services in the UK, 2006. 1. The consultant physician perspective. Diabetic Medicine, 2008, 25, 643-650.	1.2	15
206	The Hyperglycemia and Adverse Pregnancy Outcomes trial: answers but still more questions about the management of gestational diabetes. Diabetic Medicine, 2008, 25, 1013-1014.	1.2	7
207	Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists. Journal of Psychopharmacology, 2008, 22, 28-37.	2.0	48
208	Commentary on Graham et al.: Physical Effects of Short-Term rhGH Administration in Abstinent Steroid Dependency. Hormone Research in Paediatrics, 2008, 69, 355-356.	0.8	1
209	Antipsychotics and hyperprolactinaemia: Clinical recommendations. Journal of Psychopharmacology, 2008, 22, 98-103.	2.0	79
210	First- <i>v.</i> second-generation antipsychotics and risk for diabetes in schizophrenia: Systematic review and meta-analysis. British Journal of Psychiatry, 2008, 192, 406-411.	1.7	249
211	The conflict between specialist diabetes services and acute-general internal medicine for consultant diabetologists in the UK in 2006. Clinical Medicine, 2008, 8, 377-380.	0.8	5
212	The Effect of Sports Injury on Insulin-Like Growth Factor-I and Type 3 Procollagen: Implications for Detection of Growth Hormone Abuse in Athletes. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2760-2763.	1.8	35
213	Risk of Treatment-Emergent Diabetes Mellitus in Patients Receiving Antipsychotics. Annals of Pharmacotherapy, 2007, 41, 1593-1603.	0.9	57
214	Validation of the growth hormone (GH)-dependent marker method of detecting GH abuse in sport through the use of independent data sets. Growth Hormone and IGF Research, 2007, 17, 416-423.	0.5	67
215	The current and future roles of the consultant diabetologist. Diabetic Medicine, 2007, 24, 929-930.	1.2	1
216	Long-term maintenance of weight loss in patients with severe mental illness through a behavioural treatment programme in the UK. Acta Psychiatrica Scandinavica, 2007, 115, 286-294.	2.2	66

#	ARTICLE	IF	CITATIONS
217	Beyond reasonable doubt: catching the growth hormone cheats. <i>Pediatric Endocrinology Reviews</i> , 2007, 4, 228-32.	1.2	11
218	Exercising in the cold inhibits growth hormone secretion by reducing the rise in core body temperature. <i>Growth Hormone and IGF Research</i> , 2006, 16, 125-131.	0.5	21
219	Growth Hormone, Exercise and Energy Expenditure in the Metabolic Syndrome. , 2006, , 353-380.		0
220	Association between antipsychotic drugs and diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2006, 8, 125-135.	2.2	58
221	Gender differences in the insulin-like growth factor axis response to a glucose load. <i>Acta Physiologica</i> , 2006, 187, 371-378.	1.8	27
222	Antipsychotic drugs and diabetes— an application of the Austin Bradford Hill criteria. <i>Diabetologia</i> , 2006, 49, 1467-1476.	2.9	57
223	Electrical muscle stimulation acutely mimics exercise in neurologically intact individuals but has limited clinical benefits in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2005, 7, 344-351.	2.2	23
224	The introduction of a specific request form for the diagnosis of gestational diabetes (GDM) improves understanding of GDM amongst clinicians but does not increase its detection. <i>Diabetic Medicine</i> , 2005, 22, 507-508.	1.2	1
225	Alternative Site Self Blood Glucose Testing Is Preferred by Women with Gestational Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2005, 7, 604-608.	2.4	7
226	Obesity - an epidemic of the twenty-first century: an update for psychiatrists. <i>Journal of Psychopharmacology</i> , 2005, 19, 6-15.	2.0	16
227	Diabetes and schizophrenia 2005: are we any closer to understanding the link?. <i>Journal of Psychopharmacology</i> , 2005, 19, 56-65.	2.0	89
228	Challenges in Detecting the Abuse of Growth Hormone in Sport. <i>Clinical Chemistry</i> , 2005, 51, 1587-1593.	1.5	74
229	Investigating the role of the growth hormone—insulin-like growth factor (GH—IGF) axis as a determinant of male bone mineral density (BMD). <i>Bone</i> , 2005, 37, 833-841.	1.4	37
230	Diagnosis, epidemiology and pathogenesis of diabetes mellitus: An update for psychiatrists. <i>British Journal of Psychiatry</i> , 2004, 184, s55-s63.	1.7	60
231	Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. <i>British Journal of Psychiatry</i> , 2004, 184, s67-s71.	1.7	167
232	Schizophrenia, the metabolic syndrome and diabetes. <i>Diabetic Medicine</i> , 2004, 21, 515-523.	1.2	121
233	Time to move beyond glycosylated haemoglobin. <i>Diabetic Medicine</i> , 2004, 21, 655-656.	1.2	12
234	Serum insulin-like growth factor-I concentrations in late middle age: no association with birthweight in three UK cohorts. <i>Acta Physiologica Scandinavica</i> , 2004, 180, 359-366.	2.3	11

#	ARTICLE	IF	CITATIONS
235	Understanding schizophrenia and diabetes. British Journal of Hospital Medicine, 2004, 65, 485-488.	0.3	10
236	The role of the growth hormone-insulin-like growth factor axis in glucose homeostasis. Diabetic Medicine, 2003, 20, 3-15.	1.2	186
237	A postnatal fasting plasma glucose is useful in determining which women with gestational diabetes should undergo a postnatal oral glucose tolerance test. Diabetic Medicine, 2003, 20, 594-598.	1.2	44
238	Serum Insulin-like Growth Factor (IGF)-I and IGF-Binding Protein-1 in Elderly People: Relationships with Cardiovascular Risk Factors, Body Composition, Size at Birth, and Childhood Growth. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1059-1065.	1.8	76
239	Intrauterine Growth, the Vascular System, and the Metabolic Syndrome. Seminars in Vascular Medicine, 2002, 2, 033-044.	2.1	19
240	Fetal programming of the growth hormone-insulin-like growth factor axis. Trends in Endocrinology and Metabolism, 2002, 13, 392-397.	3.1	135
241	Meningitis Four Years after Treatment of Macroprolactinoma. Journal of the Royal Society of Medicine, 2002, 95, 501-502.	1.1	1
242	Computer assisted learning is an effective way of teaching endocrinology. Clinical Endocrinology, 2001, 55, 537-542.	1.2	29
243	Aging and Physical Fitness Are More Important Than Obesity in Determining Exercise-Induced Generation of GH. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5715-5720.	1.8	43
244	Nasogastric feeding enhances nutritional status in paediatric liver disease but does not alter circulating levels of IGF-I and IGF binding proteins. Clinical Endocrinology, 2000, 52, 217-224.	1.2	43
245	Physical Health of People with Mental Illness. , 0, , 277-299.		0
246	Aging and Physical Fitness Are More Important Than Obesity in Determining Exercise-Induced Generation of GH. , 0, .		20